Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Trickle Portfolio -- Ignore unavailable to you. Want to Upgrade?

To: tuck who wrote (1066)	2/21/2002 11:31:01 AM
From: tuck	Read Replies (1) \| Respond to of 1784

Given the price action in QGENF over the last three days to the present, the Robbie Stevens downgrade today is most interesting. QGENF got whacked on no news for the prior two days, but is up on a tough morning today -- the morning the downgrade was publicly issued. Obviously, this does little to endear me to Robbie Stevens, as someone who is not a big client of theirs. Sheesh. But Trickle's buy at $16.10 is looking OK so far, so maybe I should thank them for the opportunity, if grudgingly. Meanwhile, BCOR reports, and it isn't good. Almost sold this a few days ago to raise more cash. 20/20 hindsight. >>UPPSALA, Sweden, Feb. 21, 2002 (PRIMEZONE via COMTEX) -- Biacore (Nasdaq: BCOR chart, msgs): -- Biacore's sales in the fourth quarter of 2001 increased by 6% to SEK 175.0 million (165.3). For the full-year 2001, sales increased by 24% to SEK 543.7 million (438.8). -- Biacore continued its strategy of investing in developing its successful business with the pharmaceutical and biotechnology industries, as well as the commercialization of its unique SPR array chip technology. As a result of these investments and a one-off pension cost in the fourth quarter, full year earnings per share fell by 16% to SEK 5.04 (6.02). Earnings per share in the last quarter fell to SEK 1.68 (2.80). Excluding the one-off cost, earnings per share amounted to SEK 6.32 for the full-year and SEK 2.97 in the last quarter 2001. -- Biacore(r)S51, the Company's first new high-performance system for lead optimization and certain specific ADME applications, has been well accepted by the market with sales made to a number of companies including Millennium and Roche. -- Biacore signed an important collaboration with Bruker Daltonics Inc., which is designed to commercialize the combination of SPR and mass spectrometry for functional proteomics applications. -- Dr. Ulf Jonsson was appointed Chief Executive Officer of Biacore International AB effective January 1, 2002. As of the same date, Lars- Goran Andren, Biacore's previous Executive Chairman and CEO, became the Company's Non-Executive Chairman. -- Biacore is confident about its future growth prospects and expects its sales to increase by approximately 20% in 2002, with substantial quarterly variations. After substantial investments during 2001, combined marketing and administration costs are expected to increase by no more than 10% in 2002. In addition to the Company's on-going level of R&D spending, which is targeted at 15% of sales, Biacore plans to invest in the region of SEK 35 million in 2002 on commercializing its SPR array chip technology. January - December October - December 2001 2000 Change 2001 2000 Change Sales, SEK million 543.7 438.8 +24% 175.0 165.3 +6% Operating income, SEK million 64.1 78.0 -18% 25.7 37.6 -32% Operating margin, % 12 18 15 23 Income after financial items, SEK million 77.9 86.7 -10% 27.7 40.6 -32% Diluted earnings per share, SEK 5.04 6.02 -16% 1.68 2.80 -40% This information was brought to you by Waymaker waymaker.net The following files are available for download: www.waymaker.net/bitonline/2002/02/21/20020221BIT00100/bit0002.doc The Full Year-End Report www.waymaker.net/bitonline/2002/02/21/20020221BIT00100/bit0002.pdf The Full Year-End Report<< Cheers, Tuck